Khabele, Dineo <br/><br/>
Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: implications for therapy.  [electronic resource] 

 -  Cancer biology & therapy  May 2007 
 - 795-801 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1555-8576 
<br/><br/><label>Standard No.: </label>10.4161/cbt.6.5.4007  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acetylation<br/>Adult<br/>Aged<br/>Antibiotics, Antineoplastic--pharmacology<br/>Blotting, Western<br/>Butyrates--pharmacology<br/>Carcinoma, Papillary--drug therapy<br/>Cell Proliferation--drug effects<br/>Cystadenocarcinoma, Serous--drug therapy<br/>Depsipeptides--pharmacology<br/>Disease Progression<br/>Enzyme Inhibitors--pharmacology<br/>Female<br/>Gene Expression Regulation, Enzymologic<br/>Gene Silencing--drug effects<br/>Histone Deacetylase 1<br/>Histone Deacetylases--genetics<br/>Humans<br/>Hydroxamic Acids--pharmacology<br/>Middle Aged<br/>Ovarian Neoplasms--drug therapy<br/>RNA, Small Interfering--pharmacology<br/>Transcription, Genetic<br/>Tumor Cells, Cultured--drug effects<br/>Tumor Stem Cell Assay<br/>Vorinostat